Form 4: Vera Therapeutics Director Acquires Stock Options

Vera Therapeutics Director Christy J. Oliger acquired 17,084 stock options with an exercise price of $34.35, vesting under specific conditions related to service and company events.

Summary

• Christy J. Oliger, a Director at Vera Therapeutics, Inc., was granted 17,084 stock options on May 21, 2026.
• These options have an exercise price of $34.35 per share.
• The options are set to vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, provided the Reporting Person remains in continuous service.
• Vesting will also occur in full upon a change in control of the company, contingent on continuous service through that event.
• The underlying securities are Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a common compensation mechanism rather than a significant event impacting company fundamentals or immediate share price.

Positives

• Director's acquisition of stock options aligns their interests with shareholders.
• Vesting conditions tied to service and company milestones incentivize long-term commitment and performance.
• Potential for full vesting upon change in control offers an upside scenario for the director.

Negatives

• The exercise price of $34.35 is significantly higher than the current market price (as of the filing date, implied by the nature of Form 4 filings which report transactions, not current market data).
• Vesting is contingent on continued service, meaning the options could be forfeited if the director leaves the company before the vesting date.

Risks

• The value of the stock options is dependent on the future stock price of Vera Therapeutics, which could decline.
• The vesting schedule is subject to the company's performance and potential changes in control, introducing uncertainty.
• If the stock price does not exceed the exercise price of $34.35, the options may not be exercised profitably.

Future Outlook

The future outlook for the stock options is contingent on the company's stock performance relative to the $34.35 exercise price and the satisfaction of vesting conditions, including continuous service and potential change in control events.

Management Comments

• The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
• Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to align executive compensation with shareholder value and incentivize long-term growth and strategic objectives.

Stakeholder Impact

• Shareholders: The alignment of director interests with shareholders is generally positive, though the ultimate impact depends on the company's stock performance.
• Employees: The grant may signal confidence in future company growth, potentially benefiting employees through stock-based compensation or company success.
• Management: The director's compensation is directly tied to company performance and tenure.

Next Steps

• Continuous service by Christy J. Oliger through the vesting dates.
• Potential vesting upon a change in control event.
• Monitoring of Vera Therapeutics' stock performance relative to the $34.35 exercise price.

Key Dates

Keywords

Vera Therapeutics, VERA, Form 4, Stock Options, Director, Beneficial Ownership, Securities, Grant Date, Vesting Schedule, Change in Control